Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Latest Information Update: 06 Apr 2023
At a glance
- Drugs Amikacin (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
- Indications Thymic epithelial tumour
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2023 Planned primary completion date changed from 28 Feb 2022 to 30 Sep 2023.
- 01 Apr 2023 Status changed from not yet recruiting to recruiting.
- 25 Jan 2021 Planned initiation date changed from 15 Dec 2020 to 31 Jan 2021.